Novo buys into EpiDestiny’s experimental sickle cell therapy
Danish drugmaker Novo Nordisk has bought a global licence for EpiDestiny’s sickle cell disease (SCD) programme, EPI01.
Read More
Tag: EpiDestiny
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
